Aptevo Therapeutics
Open
$4.78
Prev. Close
$4.78
High
$4.78
Low
$4.78
Market Snapshot
$5.65M
-0.2
-125986.00
33
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 33 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 33 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Recently from Cashu
Please provide the content you want summarized, and I'll create a title for you.
To provide an accurate summary, I need to see the text you would like me to summarize. Please share the relevant content, and I'll be happy to help!
Summary Request for Aptevo Therapeutics Content or Industry Developments
To create an effective summary, please provide the specific content or details you would like me to summarize about Aptevo Therapeutics or relevant industry developments. This will allow me to craft a…
Please provide the content you would like summarized regarding Aptevo Therapeutics.
I apologize for the confusion, but it looks like there might have been a misunderstanding. To create the summary you're asking for, I need the specific content or text you want to be summarized regard…
Aptevo Therapeutics Initiates Reverse Stock Split to Strengthen Market Position and Attract Investors
Aptevo Therapeutics Implements Reverse Stock Split to Enhance Market Positioning Aptevo Therapeutics Inc., a Seattle-based biopharmaceutical company, announces a strategic move to conduct a one-for-ei…